ABSTRACT-
The discovery of enkephalins in 1975 (1) accelerated the research on endogenous opioid systems, leading to suc cessive isolation of various opioid peptides and fruitful investigation of their physiological, pathological and pharmacological roles (2, 3) . More recently, several groups have succeeded in molecular cloning of a-, B and x-opioid receptors (4). These findings have been stimu lating the development of novel analgesics acting via endogenous opioid systems, which has progressed along two strategies: first, direct ligands to opioid receptors, such as selective x-opioid receptor agonists (5) , and sec ond, modulators of endogenous opioids, such as enkepha linase inhibitors (6) .
Enkephalinase (neutral endopeptidase, EC. 3.4.24.11), as well as aminopeptidase, has been shown to play an important role in degrading enkephalins in vivo (7) . The inhibitors of enkephalinase have been expected to have an antinociceptive effect (6, 8), but not to elicit morphine like side effects because they do not bind directly to opioid receptors. Moreover, enkephalinase inhibitors and exogenous enkephalins have been reported to relieve forced swimming-induced immobility and conditioned suppression of motility (9) (10) (11) (12) , supporting the physio logical roles of endogenous enkephalins in stress response, mood or emotion. Various enkephalinase in hibitors have been reported in the literature (6) , and they show characteristic profiles; e.g., thiorphan, the proto type of enkephalinase inhibitor, produces an antinoci ceptive effect after i.v. and i.c.v. administration (13) . Acetorphan, a prodrug of thiorphan, shows antinocicep tive and antidepressant-like effects after i.v. administra tion (11) . In addition, RB101 (N-[(R,S)-2-benzyl-3[(S)(2 amino-4-methylthio)butyl dithio]-1-oxopropyl]-L-phenyl alanine benzyl ester) produces potent antinociceptive and antidepressant-like effects through its activity to inhibit both enkephalinase and aminopeptidase (12, 14) . However, few compounds have been demonstrated to show an antinociceptive effect after oral administration; that is, SCH34826 (15) and ONO9902 (16) .
We have aimed to develop an orally active enkepha linase inhibitor as an analgesic drug that does not cause morphine-like side effects such as drug dependency (17) . A novel compound, BL-2240 ((±)-3-(2-benzyl-3-mercapto propionyl) amino-5-methylbenzoic acid), was found to inhibit enkephalinase potently, and its prodrug, BL-2401
propionyl]amino-5 methylbenzoic acid), was synthesized as an orally active antinociceptive compound. BL-2401 was metabolized to BL 2240; a pharmacokinetic study demonstrated that BL-2240 was detected in the plasma and brain of mice and rats after oral administration of BL-2401 (K. Hayashi and M. Miyamoto, unpublished data). Thus, the present study was carried out to characterize the antinociceptive profile of BL-2401 in comparison with codeine and aspirin. We also investigated its antidepressant-like effect that might be of benefit for relief of pain; patients with pain often have depressive disorders (18) . In addition, the potency of BL-2401 in inhibiting enkephalinase was evaluated using in vitro, ex vivo and in vivo assays to ascertain the mechanism of its effects.
MATERIALS AND METHODS

Animals
ddY Mice and Wistar rats were purchased from Japan SLC (Hamamatsu) and SD rats from Clea Japan (Osaka). Animals were housed in groups (except for arthritis test) under conditions of controlled temperature (23±21C), humidity (55-L10%) and light (06:00-18:00 hr). Food and water were available ad libitum. Each animal was used only once in all experiments.
Nociceptive tests
Phenylbenzoquinone writhing test in mice (19, 20) : Female ddY mice (18-22 g) were used. Writhing was induced by i.p. injection of 10 ml/kg of 0.03% phenyl p-benzoquinone in a 5% ethanol aqueous solution. The number of writhes was counted for a 15-min period com mencing 5 min after the phenylbenzoquinone injection. When the writhes were 50% or less the mean number in the vehicle control group, the dose was considered effec tive. The anti-writhing ED50 and 95076 confidence limits were calculated from the effective rates (% of number of mice in which the dose was effective/number of mice test ed) according to the method of Litchfield and Wilcoxon (21) . BL-2401 and other test drugs were orally admin istered 30 min before the injection of phenylbenzoqui none. Intracisternal (i.c.) administration of naloxone hydrochloride was performed in a volume of 10 p1/mouse according to the method of Ueda et al. (22) .
Acetic acid writhing test in rats (20, 23) Paw pressure test in adjuvant-induced arthritic rats: A 10 mg/ml suspension of adjuvant (Mycobacterium butyricum; Difco, Detroit, MI, USA) was prepared using light mineral oil (Bayol F). A 0.06 ml volume of this sus pension was injected intradermally into the root of the tail of female SD rats (8-weeks-old). Two weeks later (day 14), rats showing arthritis in their hind paws were select ed, and they were orally administered BL-2401 or codeine phosphate once a day during the following 7 days (days [14] [15] [16] [17] [18] [19] [20] . The nociceptive threshold of the hind paw for mechanical stimulation was measured with the apparatus cited in the section on the tail pressure test, and the pres sure to elicit either a struggle response or paw withdrawal was determined. The cut-off pressure was 50 mm. The pressure test was done before and 1 hr after drug ad ministration on day 14 and at 1 hr after drug administra tion on days 16, 18 and 20. On days 21 and 28 (1 and 8 days after the last administration), only the pressure test was done. In the Results section, the scale of the pressure threshold was represented by g.
Antidepressant tests
Forced-swimming test in mice (26): Male ddY mice (25 32 g) were dropped into a vertical cylinder contain ing 15 cm of water at 21-231C and left there for 6 min.
The total duration of immobility during the last 4 min was measured. Mice were treated orally with BL-2401 1 hr before the test.
In vitro enkephalinase inhibition assay Enzyme preparation: Enkephalin-degrading enzymes were prepared from rat striata according to the method of Gorenstein and Snyder (27) with minor modification. The striata from male Wistar rats (200-300g) were homogenized in 30 vol. 50 mM Tris-HC1 buffer (pH 7.7) with a glass-Teflon homogenizer. The homogenate was centrifuged at 1,000 x g for 15 min, and then the super natant was centrifuged at 50,000 x g for 15 min. The pellet was washed three times according to the above described procedure. The resulting pellet was resuspended in 15 vol. 50 mM Tris-HC1 buffer (pH 7.7) containing 1 % Triton X-100 and then incubated at 37V for 45 min, followed by centrifugation at 100,000 x g for 1 hr. The supernatant containing solubilized enzymes was applied to a DEAE-cellulose column previously equilibrated with 50 mM Tris-HCl buffer (pH 7.7) containing I % Triton X 100. Elution was done with two bed volumes of 50 mM Tris-HCl buffer (pH 7.7) containing 1010 Triton X-100 followed by a linear salt gradient from 0 to 0.4 M NaCI. These procedures were carried out at 41C except for the incubation. Under these conditions, enkephalinase activ ity was detected in the void volume, and aminopeptidase and dipeptidylaminopeptidase were eluted within the NaCI gradient. These fractions were used as enzyme preparations.
Enzyme assay: [3H]Leucine-enkephalin was used as a substrate. After pre-incubation of enzyme (50 pl) and test compound solution (25 p1) at 371C for 5 min, [3H]leucine enkephalin (25 pl, final concentration 20 nM) was added. The reaction was performed at 371C for 1 hr (10 min for dipeptidylaminopeptidase) and stopped with 25 pl of 0.2 N HCI. A 50 pl aliquot of reaction mixture was applied to a Pasteur pipette containing polystyrene beads (Porapak Q) (28) . The substrate, but not its metabolites, was retained on the beads. The metabolites were eluted with 3 x 1 ml of water from the column. The reactions progressed linearly at the initial velocity. Test compounds were dissolved in ethanol and diluted with 50 mM Tris HC1 buffer (pH 7.7). IC50 values were calculated from inhibitory rates at three to four concentrations according to logit log analysis. The inhibitory rate was estimated from two or three experiments.
Ex vivo enkephalinase inhibition assay (11) Female ddY mice (17-25 g) were treated orally with BL-2401. The mice were sacrificed with cervical disloca tion; the right ventricle of the heart was then incised, and saline (20 ml) was injected into the left ventricle to ex clude blood from the brain. The striata were dissected and homogenized with 1 ml of 50 mM Tris-HCl buffer (pH 7.4). The homogenate (50 p1) was incubated for 30 min at 25V with [3H](D-A1a2,Leu5)-enkephalin (25 pl, final con centration 20 nM), bestatin (10 pM) and captopril (1 pM) and with or without thiorphan (1 pM) (final volume: 100 pl). The reaction was stopped with 25 pl of 0.2 N HCI, and then a 50-pl aliquot of the reaction mixture was applied to a Porapak Q column. The metabolite ([3H]Tyr-D-Ala-Gly) was eluted with 3 x 1 ml of water. Enkephalinase activity was calculated as the difference of metabolite production between the reaction in the presence of thiorphan and that in its absence. Protein was assayed with Lowry's method (29) .
(D-Ala2,Met5)-enkephalin (DAME) potentiation test (in vivo assay for enkephalinase inhibition) (13) DAME administered into the brain is degraded by enkephalinase, but not by aminopeptidase; therefore, enkephalinase inhibitors are able to potentiate the anti nociceptive activity of DAME. This test has been used for an in vivo enkephalinase inhibition assay. Male ddY mice (20-26 g) were administered intracisternally with DAME (1 pg/mouse) at various intervals after oral ad ministration of BL-2401. Antinociceptive effect was as sessed by the tail pressure test. In the time-course study, DAME was given only once to each mouse pre-treated with BL-2401.
Materials
BL-2401, BL-2240, thiorphan and captopril were syn thesized in our laboratory. Naloxone hydrochloride and phenyl p-benzoquinone (Sigma Chemical Co., St. Louis, MO, USA), codeine phosphate (Dainippon Pharmaceuti cal Co., Osaka), bestatin and DAME (Peptide Institute, Minoh), DEAE-cellulose (Chisso, Chiba), Porapak Q (100-120 mesh; Waters Associates, Milford, MA, USA), [3H]leucine-enkephalin (New England Nuclear, Boston, MA, USA), [3H](D-Ala2,Leu5)-enkephalin (CEA, Gif sur-Yvette, France), aspirin (Nacalai Tesque, Kyoto) and other reagents (Nacalai Tesque, and Wako, Osaka) were used. BL-2401, codeine phosphate and aspirin were sus pended in 0.5010 tragacanth gum for oral administration, and DAME and naloxone hydrochloride were dissolved in saline. These compounds were administered at volumes of 10 ml/kg (mice; p.o., s.c., i.v.), 5 ml/kg (rat acetic acid writhing test; p.o., s.c.) or 3 ml/kg (rat arthritis test; p.o.).
Statistical analyses
Results are presented as the mean with S.E. Statistical difference was estimated by the Dunnett's test or Bonfer roni multiple comparison test (for naloxone antagonism). 
RESULTS
Antinociceptive effect
In the mouse phenylbenzoquinone writhing test, BL 2401 inhibited the writhes at doses of 10-100 mg/kg, p.o. (Table 1) , with an ED50 value (95% confidence limits: C.L.) of 12.4 (8.4-18.4) mg/kg. ED50s of codeine phos phate and aspirin were 15.6 (8.7 28.1) (n = 31) and 126.5 (77.1-207.5) (n=18) mg/kg, respectively. To estimate the duration of the action, BL-2401 was orally admin istered 3 and 6 hr before the injection of phenylbenzo quinone. The anti-writhing activity of BL-2401 (50 and 100 mg/kg) was still significant 6 hr after administration; the inhibitory rates were 38.3010 (P<0.01) and 54.6% (P < 0.01), respectively. The ED50s at 3 and 6 hr after ad ministration were 21.4 (11.4-40.0) and 75.4 (52.6-108) mg/kg, respectively. To clarify the involvement of opioid receptors in the action of BL-2401, naloxone antago nism was tested. As shown in Fig. 1 , the anti-writhing activity produced by BL-2401 (100 mg/kg, p.o.) was sig nificantly reduced by naloxone hydrochloride at doses of 0.1-0.5 mg/kg, i.v. To further test the involvement of central opioid receptors, naloxone hydrochloride was in jected i.c. As shown in Fig. 1 , the anti-writhing activity of BL-2401 (100 mg/kg) was also reduced by i.c. injected naloxone hydrochloride at a dose of 0.5 pg/mouse (ca. 0.025 mg/kg), a dose of naloxone hydrochloride which did not show antagonism after i.v. administration. In the rat acetic acid writhing test, BL-2401 produced a dose related inhibition of writhes with an ED50 (95% C.L.) of 55.8 (29.0-107) mg/kg ( Table 1 ). ED50s of codeine phosphate and aspirin were 14.2 (8.6 23.5) (n = 32) and 16.9 (8.8 32.5) (n =18) mg/kg, respectively. Naloxone hydrochloride (0.5 mg/kg, s.c.) significantly reduced the anti-writhing activity of BL-2401 (160 mg/kg, p.o.).
In the mouse tail pressure test, BL-2401 (400 mg/kg, p.o.) produced a modest antinociceptive effect (Fig. 2) , while codeine phosphate produced a marked antinocicep tive effect at doses of 20-80 mg/kg. Aspirin (800 mg/kg) had no significant effect. In the mouse hot-plate test, BL 2401 significantly prolonged the jump latency at doses of 200 and 400 mg/kg (Fig. 3) . Codeine phosphate showed significant prolongation at doses of 20 and 40 mg/kg (Fig. 3) . Aspirin had no effect; the mean and S.E. for 12 mice were 147.8± 14.8 and 163.0± 15.8 (sec) for vehicle and 800 mg/kg, respectively. The licking latency was not affected by any doses. In the adjuvant-induced arthritic rats, hyperalgesia was observed throughout the test period; the pressure threshold for arthritic rats (119± 10 g, n=20, day 14) was significantly lower than that for normal rats (212± 11 g, n=20, day 14). BL-2401 partially but significantly relieved the hyperalgesia at doses of 30 and 100 mg/kg (Fig. 4) . However, its dose-response relation was not clear. Codeine phosphate (100 mg/kg) markedly in creased the pressure threshold, which rose over the nor mal level. One and 8 days after the last administration, the thresholds in all treated groups returned to the level for the vehicle control group. BL-2401 and codeine phos phate did not affect the hind paw volume. 
Antidepressant-like effect
In the mouse forced-swimming test, BL-2401 sig nificantly reduced the duration of immobility at a dose of 100 mg/kg (Fig. 5) . The decrease induced by BL-2401 (100 mg/kg) was reversed by s.c. administered naloxone hydrochloride (0.5 mg/kg). ity in the striata was dose-dependently inhibited (Fig. 6) ; the inhibitory rates were 24.0%, 41.107o and 63.6% for 5, 25 and 100 mg/kg, respectively. Furthermore, the time course study showed that BL-2401 (100 mg/kg) produced potent inhibition throughout 8 hr after oral administra tion; the inhibitory rates were 80.5%, 76.6%, 67.2% and 48.4% at 1, 2, 4 and 8 hr after administration, respec tively. In the DAME potentiation test, BL-2401, when given 30 min before DAME, dose-relatedly potentiated the antinociceptive effect of DAME (Fig. 7) . In addition, time-course studies of the potentiation induced by BL 2401 were performed at doses of 50 and 100 mg/kg (p.o.). As shown in Fig. 8 , significant potentiation was still detected 8 hr after the administration of either dose of BL-2401. BL-2401 alone (up to 100 mg/kg, p.o.) did not significantly affect the pressure threshold. .01, significantly different from the vehicle control group. Fig. 7 . Potentiation of antinociceptive activity of (D-Ala2,Met5) enkephalin (DAME) by BL-2401 in the tail pressure test in mice. BL-2401 was orally administered 30 min before i.c. injection of DAME (1 ,ug/mouse). [:1, vehicle (p.o.) + saline (i.c.); /, vehicle (p.o.) + DAME; A, BL-2401 (10 mg/kg) + DAME; 0, BL-2401 (50 mg/kg) + DAME; 0, BL-2401 (100 mg/kg) + DAME. n = 7 8. **P < 0.01, significantly different from DAME alone. Data were previously analyzed by repeated measures analysis of variance, indicating significant (P<0.01) interaction between treatment and time. Fig. 8 . Time course of the DAME potentiation induced by BL 2401 in the tail pressure test in mice. DAME (1 pg/mouse) was given i.c. at various intervals after the oral administration of BL-2401 (50 and 100 mg/kg), and pressure threshold was measured 5 min after DAME injection. El, vehicle (p.o.) + DAME; ®, BL-2401 (50 mg/kg, p.o.) + DAME; ®, BL-2401 (100 mg/kg, p.o.) + DAME. n=4-8. **P<0.01, significantly different from DAME alone.
DISCUSSION
In the nociceptive tests using acute experimental pain models, BL-2401 produced an antinociceptive effect after oral administration, and its antinociceptive profile was different from that of codeine phosphate, an opioid agonist, and aspirin, a non-steroidal anti-inflammatory drug (NSAID). The minimum effective dose (MED)s of BL-2401 were 10 mg/kg (phenylbenzoquinone writhing test), 40 mg/kg (acetic acid writhing test), 200 mg/kg (hot plate test) and 400 mg/kg (tail pressure test). The differ ence in effective doses among tests was larger in compari son with that of codeine phosphate; the MEDs of codeine were 5, 10, 20 and 20 mg/kg, respectively. Furthermore, in the hot plate and the tail pressure tests, the effect elic ited by BL-2401 occurred to a small degree compared to that elicited by codeine phosphate. On the other hand, aspirin showed antinociceptive effects in the writhing tests only, and its anti-writhing potency in rats (acetic acid writhing test) was more potent than that in mice (phenyl benzoquinone writhing test), similar to the potency ratio for other NSAIDs (30) . Thus, BL-2401 was demonstrated to possess a characteristic antinociceptive profile that was different from those of opioid agonists and NSAIDs.
Chronic pain is demonstrated to differ from acute pain in certain aspects such as the nervous route of the per ception (31) . It is conceivable that a novel compound shows different antinociceptive potencies against chronic and acute pain. Thus, the antinociceptive activity of BL 2401 was tested in adjuvant-induced arthritic rats as a model of chronic pain. BL-2401 relieved hyperalgesia ob served in the arthritic rats, and this effect was not at tenuated by repeated administration. The reason why the significant effect appeared in the latter part of dosing term is unclear. At least, it is unlikely caused by the accumula tion of BL-2240 or BL-2401 in the body after repeated dosing because on day 21 (one day after the last admin istration), the pressure thresholds in the BL-2401-treated groups reduced to the level in the vehicle group. The effect induced by BL-2401 was slight, unlike the effect of codeine phosphate, which elicited an increase over the threshold for normal rats. This different potency may be related to the distinct mechanism of actions of BL-2401 and opioid analgesics. BL-2401 did not show an anti inflammatory effect, unlike the known action of NSAIDs, which decrease the edema of the arthritic paws. NSAIDs produce their antinociceptive and anti-inflammatory ac tion via inhibiting cyclooxygenase and often cause gastro intestinal side-effects. BL-2401 may be without such side-effects because of the different mechanism of action. These findings suggest that BL-2401 may have an anti nociceptive effect against chronic pain.
Pain, especially a chronic one, and emotions are thought to form a vicious circle (32) . Emotions such as anxiety, fear and depression often amplify pain; mean while, pain may serve as a stressor that causes such emo tions. This is supported by the application of antianxiety and antidepressant drugs as adjuvants for clinical chronic pain (33) . The antidepressant-like activity of BL-2401 was examined in the forced swimming test which is useful for screening of antidepressants.
In this test, BL-2401 decreased the duration of immobility. It is reported, however, that some compounds with locomotor stimulant activity might cause false-positive effect in this test (26) . BL-2401 slightly increased locomotor activity in mice (Y. Seto et al., unpublished data), though not inten sively like morphine. In addition, BL-2401 inhibited the incidence of muricide behavior observed in olfactory bulbectomized rats (Y. Seto, unpublished data). These results indicate that BL-2401 possess an antidepressant like effect after oral administration. We are interested in the emotional influence on the pain suppression and the roles of endogenous opioids in emotion, and further stud ies are necessary to clarify these points.
In the present study, the antinociceptive and anti depressant-like effects of BL-2401 were antagonized by naloxone hydrochloride, suggesting the involvement of endogenous opioid systems in the effects of BL-2401. Since BL-2401 and BL-2240 did not show direct binding activity in an opioid receptor assay using isolated guinea pig ileum longitudinal muscle (A. Kita, unpublished data), the actions of BL-2401 may be mediated by en dogenous opioids, indicating the difference between BL 2401 and codeine phosphate as to the mode of the anti nociceptive action. Chipkin (8) has postulated that enkephalinase inhibitors produce an antinociceptive effect, only when endogenous enkephalinergic systems are active in response to noxious stimuli. The activation of endogenous opioid systems is estimated by certain features, i.e., hyperalgesia induced by naloxone, and increase in the release of endogenous opioids elicited by noxious stimuli. It has been previously reported that naloxone hydrochloride (1 mg/kg, i.p.) shows an algesic effect in the writhing test and the hot plate test (only jump latency) (34) , and acetic acid stimulus increases the release of enkephalin (35) . The positive effects of BL-2401 in the above-mentioned tests suggest that the antinociception elicited by BL-2401 depends on the activation of the en dogenous opioid systems.
To further clarify the mechanism responsible for the actions of BL-2401, its inhibitory activity on enkephalinase was investigated using in vitro, ex vivo and in vivo assays. In the in vitro study, BL-2240 inhibited enkephalinase selectively among the enkephalin-de grading enzymes. The ex vivo study indicated that BL 2401 given orally reached the brain and inhibited enkephalinase there. In addition, based on the ability of BL-2401 to potentiate DAME-induced antinociception, it is considered that BL-2401 may inhibit the degradation of DAME, and that of endogenous enkephalins as well. The effective doses and the time course for ex vivo and in vivo enkephalinase inhibition elicited by BL-2401 were similar to those for its anti-writhing activity, suggesting that the antinociceptive effect of BL-2401 is due to its inhibitory action on enkephalinase.
As already reported, RB101, which inhibits both enkephalinase and aminopeptidase, shows a potent anti nociceptive effect against thermal or electrical nocicep tive stimuli (14) after parenteral administration. In con trast, the antinociceptive potency of BL-2401 on the acute thermal or mechanical stimuli was modest, similar to a selective enkephalinase inhibitor such as SCH34826 (15) . However, BL-2401 showed both antinociception and anti depressant-like effects after oral administration.
In conclusion, the property of BL-2401 as a potent and selective enkephalinase inhibitor was demonstrated in the in vitro, the ex vivo and the in vivo studies. When ad ministered orally, BL-2401 produced an antinociceptive effect mediated by opioid systems, although the effect was modest against acute mechanical and physical stimuli. The different efficiency of BL-2401 from opioid analgesics and NSAIDs in various antinociceptive tests may be based on the different mechanism of action. Furthermore, BL-2401 produced antidepressant-like effects via opioid systems after oral administration to mice.
